Skip to main content
SpringerLink
Log in

Unexpected Low Efficacy of Stealth Liposomal Doxorubicin (Caelyx) and Vinorelbine in Metastatic Breast Cancer

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

In this phase II study, 23 patients with metastatic breast cancer were treated with a combination of Caelyx (40 mg/m2 on day 1) and vinorelbine (20 mg/m2 on days 1 and 8) every 4 weeks. According to the statistical design, enrollment was closed after the first stage due to the low response rate observed (four partial remissions, 12 stabilizations). Toxicity was acceptable, however, grade 3–4 neutropenia was not negligible. Our study does not support the development of this combination in advanced breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hortobagyi GN: Anthracyclines in the treatment of cancer. Drugs 54(suppl. 4): 1-7, 1997

    Google Scholar 

  2. Von Hoff DD, Layard MW, Basa P, Davis Jr HL, Von Hoff AL, Rozencweig M, Muggia FM: Risk factors for doxorubicininduced congestive heart failure. Ann Intern Med 91: 710-717, 1979

    Google Scholar 

  3. Hellman K: Anthracycline cardiac toxicity by dexrazosane: breakthrough of a barrier-sharpens antitumor profile and therapeutic index (Editorial). J Clin Oncol 14: 332-333, 1996

    Google Scholar 

  4. Bonadonna G, Gianni L, Santoro A, Bonfante V, Bidoli P, Casali P, Demicheli R, Valagussa P: Drugs 10 years later: epirubicin. Ann Oncol 4: 359-369, 1993

    Google Scholar 

  5. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Coen R, Martin F, Huang A, Barenholz Y: Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54: 987-992, 1994

    Google Scholar 

  6. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon A: Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I study. J Clin Oncol 13: 1777-1785, 1995

    Google Scholar 

  7. Alberts DS, Garcia DJ: Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 54(suppl. 4): 30-35, 1997

    Google Scholar 

  8. Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B, Patek A, Martin FJ: The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 9: 711-716, 1998

    Google Scholar 

  9. Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, Henderson R, Berry G, Gabizon A: Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses 500 mg/m2. Ann Oncol 8: 1029-1033, 2000

    Google Scholar 

  10. Ranson MR, Cheeseman S, White S, Margison J: Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. Crit Rev Oncol Hematol 37: 115-120, 2001

    Google Scholar 

  11. Laufman LR, Spiridonidis CH, Jones JJ, Rhodes VA, Wallace K: Phase I trial of doxil plus vinorelbine in patients with advanced malignancies. Proc ASCO (Am Soc Clin Oncol) 17: 246 (abstract 944), 1998

    Google Scholar 

  12. Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, Matulonis UA, Parker LM, Harris LN, Winer EP: Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol 10: 1113-1116, 1999

    Google Scholar 

  13. Norris B, Pritchard KI, James K, Myles J, Bennett K, Marlin S, Skillings J, Findlay B, Vandenberg T, Goss B, Latreille J, Rudinskas L, Lofters W, Trudeau M, Osoba D, Rodgers A: Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/ recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 18: 2385-2394, 2000

    Google Scholar 

  14. Simon R: Optimal two-stage designes for phase II clinical trials. Contr Clin Trials 10: 1-10, 1989

    Google Scholar 

  15. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in dose-finding and sequence-finding study. J Clin Oncol 13: 2688-2699, 1995

    Google Scholar 

  16. Slamon DL, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 344: 783-792, 2001

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano (MI), Italy

    Lorenza Rimassa, Carlo Carnaghi, Isabella Garassino, Piermario Salvini, Valeria Ginanni, Giuseppe Gullo, Emanuela Morenghi & Armando Santoro

Authors
  1. Lorenza Rimassa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlo Carnaghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Isabella Garassino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Piermario Salvini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Valeria Ginanni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giuseppe Gullo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Emanuela Morenghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Armando Santoro
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rimassa, L., Carnaghi, C., Garassino, I. et al. Unexpected Low Efficacy of Stealth Liposomal Doxorubicin (Caelyx) and Vinorelbine in Metastatic Breast Cancer. Breast Cancer Res Treat 77, 185–188 (2003). https://doi.org/10.1023/A:1021300719965

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1021300719965

Search

Navigation